









Markets
/
Stocks
/
nasdaq-snn
/

Smith & Nephew PLC

SNN

36.490USD

-0.680-1.83%

Close 10/23, 16:00（ET）Quotes delayed by 15 min

15.98BMarket Cap

--P/E TTM



Smith & Nephew PLC

36.490

-0.680-1.83%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Smith & Nephew PLC

Currency: USD Updated: 2025-10-23

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Smith & Nephew PLC's Score

Industry at a Glance

Industry Ranking

59 / 204

Overall Ranking

149 / 4685

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

35.157

Target Price

-3.76%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Smith & Nephew PLC Highlights

StrengthsRisks

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 5.81B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 79.37%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 79.37%.

Overvalued

The company’s latest PE is 32.47, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 33.01M shares, decreasing 26.26% quarter-over-quarter.

Held by Brandes Investmen

Star Investor Brandes Investmen holds 1.60M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-23

The company's current financial score is 8.87, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.87

Change



Financials

6.36

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

8.01

Key Metrics

Free cash flow

No Data

Smith & Nephew PLC's Company Valuation

Currency: USD Updated: 2025-10-23

The company’s current valuation score is 3.98, which is lower than the Healthcare Equipment & Supplies industry's average of 7.16. Its current P/E ratio is 32.47, which is 6.06% below the recent high of 34.43 and 22.04% above the recent low of 25.31.

Score

Industry at a Glance

Previous score

3.98

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 59/204

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-23

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.72. The average price target for Smith & Nephew PLC is 36.75, with a high of 41.00 and a low of 26.13.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

35.157

Target Price

-3.76%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

115

Total

Median

Average

Company name

Ratings

Analysts

Smith & Nephew PLC

SNN

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-23

The company’s current price momentum score is 8.77, which is higher than the Healthcare Equipment & Supplies industry's average of 7.16. Sideways: Currently, the stock price is trading between the resistance level at 37.77 and the support level at 34.95, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.21

Change

-0.44

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.281

Neutral

RSI(14)

53.501

Neutral

STOCH(KDJ)(9,3,3)

75.886

Neutral

ATR(14)

0.509

Low Volatility

CCI(14)

101.813

Buy

Williams %R

36.170

Buy

TRIX(12,20)

-0.068

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

36.572

Sell

MA10

35.962

Buy

MA20

35.984

Buy

MA50

36.700

Sell

MA100

33.849

Buy

MA200

30.499

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-23

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.37. The latest institutional shareholding proportion is 7.78%, representing a quarter-over-quarter decrease of 2.27%. The largest institutional shareholder is Brandes Investmen, holding a total of 1.60M shares, representing 0.38% of shares outstanding, with 21.26% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BMO Capital Markets (US)

3.20M

+455.42%

River Road Asset Management, LLC

3.18M

+9.30%

Scharf Investments, LLC

2.08M

+0.34%

Brandes Investment Partners, L.P.

Star Investors

1.60M

+4.14%

J.P. Morgan Securities plc

1.18M

Optiver Holding B.V.

1.15M

+714.32%

Goldman Sachs Asset Management, L.P.

1.08M

-1.72%

Goldman Sachs International

994.78K

+49.64%

Parametric Portfolio Associates LLC

971.46K

-0.14%

Risk Assessment

Currency: USD Updated: 2025-10-23

The company’s current risk assessment score is 8.82, which is higher than the Healthcare Equipment & Supplies industry's average of 4.64. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.